Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PENNVAX-G
- Development stage
- Phase 1
- Lead developer
- Inovio Pharmaceuticals
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
PENNVAX-G is a DNA vaccine candidate developed by Inovio Pharmaceuticals in collaboration with the University of Pennsylvania for the prevention of HIV-1 infection. It is a multi-clade, multi-antigen vaccine designed using Inovio's SynCon technology to target HIV-1 clades A, C, and D. The vaccine consists of four DNA plasmids encoding synthetic consensus Env and Gag proteins. PENNVAX-G is typically administered via intramuscular injection, often enhanced by electroporation using the CELLECTRA device or delivered via the Biojector 2000 needle-free system to improve cellular uptake and immunogenicity. In clinical trials, such as the Phase I RV262 study, it has been evaluated as a prime in a heterologous prime-boost regimen followed by a viral vector boost, such as MVA-CMDR.
- Brand names
- PENNVAX-G
- Other names
- PENNVAX-G DNAPVG DNAPENNVAX-G DNA (ENV & GAG)
02
Targets
Gag (HIV-1 Gag polyprotein)Pol (HIV-1 Pol polyprotein)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on PENNVAX-G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PENNVAX-G.